Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258875 | 0.85 | ALDH1A1 (0.47) | TSHRALDH1A1NOS1NOS2KDM1A | |
| SCHEMBL4200353 | 0.82 | NOS1 (0.49) | TSHRALDH1A1NOS1NOS2KDM1A | |
| SCHEMBL30704883 | 0.82 | NOS1 (0.49) | TSHRALDH1A1NOS1NOS2KDM1A | |
| SCHEMBL23134330 | 0.81 | NOS1 (0.51) | TSHRALDH1A1NOS1NOS2KDM1A | |
| SCHEMBL18905641 | 0.81 | TSHR (0.48) | TSHRTAAR1APPHTR6 | |
| SCHEMBL989636 | 0.80 | ALDH1A1 (0.67) | TSHRALDH1A1NOS1HTR7CHRNB2 | |
| SCHEMBL24093147 | 0.79 | ALDH1A1 (0.45) | TSHRALDH1A1NOS1NOS2KDM1A | |
| SCHEMBL15034736 | 0.79 | ALDH1A1 (0.45) | TSHRALDH1A1NOS1NOS2KDM1A | |
| SCHEMBL23133807 | 0.79 | ALDH1A1 (0.45) | TSHRALDH1A1NOS1NOS2KDM1A | |
| SCHEMBL3617649 | 0.77 | RAPGEF4 (0.55) | TSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397354-B1 | IMIDAZOLE-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2005-10-26 | — | — | EP | claimed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20210087184-A1 | AMINO-BENZOISOTHIAZOLE AND AMINO-BENZOISOTHIADIAZOLE AMIDE COMPOUNDS | ALCON INC. (CH) | 2021-03-25 | — | — | US | disclosed |
| EP-3319955-B1 | 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS | GILEAD SCIENCES INC (US) | 2020-11-25 | — | — | EP | disclosed |
| WO-2020210381-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2019178324-A1 | AMINO-BENZOISOTHIAZOLE AND AMINO-BENZOISOTHIADIAZOLE AMIDE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| EP-2349990-B1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | PIMCO 2664 LTD (GB) | 2018-05-02 | — | — | EP | disclosed |
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013086451-A2 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20110201608-A1 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | TSHR 1941/4885ALDH1A1 2379/4885NOS1 4527/4885 |
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK6 | TSHR 2406/4885ALDH1A1 2953/4885NOS1 4598/4885 |
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK5 | TSHR 2964/4885ALDH1A1 3172/4885NOS1 4681/4885 |
| US-20110201608-A1 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | NR4A1, NR4A3, NR0B1 | TSHR 313/4885ALDH1A1 1585/4885NOS1 544/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | TSHR 4317/4885ALDH1A1 2622/4885NOS1 3953/4885 |
| US-20210087184-A1 | AMINO-BENZOISOTHIAZOLE AND AMINO-BENZOISOTHIADIAZOLE AMIDE COMPOUNDS | ATM, MAP3K15, MAP3K3 | TSHR 2517/4885ALDH1A1 3004/4885NOS1 272/4885 |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | IL2, NFATC1, IL2RA | TSHR 4016/4885ALDH1A1 3523/4885NOS1 1860/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | TSHR 3155/4885ALDH1A1 1936/4885NOS1 4640/4885 |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | SMN1; SMN2, PYGB, PMP22 | TSHR 4760/4885ALDH1A1 2566/4885NOS1 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.